Imipenem–cilastatin-induced thrombocytosis: A probable rare case report

Author:

Chen Huadong1ORCID,Xu Xing’e1,Li Piaopiao1,Xu Zhenglin2

Affiliation:

1. Pharmacy Department, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China

2. Urinary Surgery, Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang, China

Abstract

Drug-induced thrombocytosis is difficult to identify and is rarely reported. Here, we report a probable rare case of imipenem–cilastatin-induced thrombocytosis in a 51-year-old female. The patient received imipenem–cilastatin treatment because of an intra-abdominal infection, following which the platelet count increased to a peak value of 1058×109 cells/L in 14 days. When imipenem–cilastatin was replaced by levofloxacin and amikacin, the platelet count decreased progressively and remained within the normal range until the 6-month follow-up. Moreover, platelet counts were independent of the infection. Thrombocytosis was probably attributable to imipenem–cilastatin with a Naranjo score of seven. This is a probable rare case in which the thrombocytosis was likely an adverse reaction induced by imipenem–cilastatin. We suggest that clinicians need to be vigilant concerning the impact of imipenem–cilastatin on platelet count in patients with thrombocytosis.

Funder

Jinhua Science and Technology Bureau

Publisher

SAGE Publications

Subject

Immunology,Immunology and Allergy,General Medicine

Reference13 articles.

1. Two decades of imipenem therapy

2. Comparative Review of the Carbapenems

3. Imipenem-cilastatin in pediatric patients

4. Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections

5. US Food and Drug Administration. PRIMAXIN® (Imipenem and Cilastatin) for Injection, for Intravenous Use, 2018, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050587s081lbl.pdf (accessed on January 10, 2020).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Imipenem/cilastatin;Reactions Weekly;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3